{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001838","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.104316+00:00","generated_at":"2026-05-15T09:21:25.917556+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures","bullets":["Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.","Net loss $33.5M for 2025 vs $69.9M in 2024; revenue $14.1M, up from $6.2M.","Moderna settlement: $950M noncontingent due July 2026; contingent $1.3B on 1498 ruling. Arbutus gets 20% of noncontingent after costs.","Two additional imdusiran Phase 2a patients achieved functional cure for chronic HBV, total 10 to date.","Company evaluating return of capital to shareholders in Q3 2026 after Moderna payment receipt."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001838","json":"https://secwatch.observer/filing/0001171843-26-001838.json","markdown":"https://secwatch.observer/filing/0001171843-26-001838.md","text":"https://secwatch.observer/filing/0001171843-26-001838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/f8k_032026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:21:25.917556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc65558b0b252b082970718ef56b0960ffbb0e37","claim":"Arbutus Biopharma Corp reported the fourth quarter and year ended December 31, 2025 results: revenue $14.1 million.","evidence_excerpt":"one-time payments related to its restructuring efforts. This was partially offset by $5.5 million of proceeds from the exercise of stock options. Revenue Total revenue was $14.1 million for the year ended December 31, 2025, compared to $6.2 million for the same period in 2024. The increase of $7.9 million was due to the recognition of all previously-deferred","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/0001171843-26-001838-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2025"},{"label":"Revenue","value":"$14.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}